US3336196A - Antidepressant compositions - Google Patents

Antidepressant compositions Download PDF

Info

Publication number
US3336196A
US3336196A US380657A US38065764A US3336196A US 3336196 A US3336196 A US 3336196A US 380657 A US380657 A US 380657A US 38065764 A US38065764 A US 38065764A US 3336196 A US3336196 A US 3336196A
Authority
US
United States
Prior art keywords
epoxypropyl
benzyl
oil
compositions
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US380657A
Inventor
Mcgregor Donald Neil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Co
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Priority to US380657A priority Critical patent/US3336196A/en
Application granted granted Critical
Publication of US3336196A publication Critical patent/US3336196A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/36—Compounds containing oxirane rings with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D331/00—Heterocyclic compounds containing rings of less than five members, having one sulfur atom as the only ring hetero atom
    • C07D331/02—Three-membered rings

Definitions

  • compositions of the present invention comprise a quaternary salt of certain N,N-dimethylbenzylamines as an essential active ingredient in combination with a pharmacologically acceptable anion.
  • the compositions of the present invention possess valuable therapeutic utility as antidepressants and it is the object of the present invention to provide a novel method of counteracting mental depression and apathy without stimulating motor activity.
  • the therapeutic ingredient is, in the preferred form of the present invention, a quaternary ammonium salt of an N,N-dimethylbenzylamine which can be represented by the following formula:
  • R is a member of the group 2,3-epoxypropyl, 2, S-epithiopropyl or 2,3-dihydroxypropyl, and X is a nontoxic anion.
  • the nontoxic anions which would be pharmaceutically acceptable include the halides (chloride, bromide and' iodide), (lower)alkyl sulfates, the alkyl and aryl sulfonates, phosphate, maleate, fumarate, succinate, tartrate, oxalate and citrate and other ones known to the art.
  • halides chloride, bromide and' iodide
  • (lower)alkyl sulfates the alkyl and aryl sulfonates
  • phosphate maleate, fumarate, succinate, tartrate, oxalate and citrate
  • the salts obtained through these variations of X may in some cases have special advantages due to solubility, ease of crystallization, lack of objectionable taste, etc. but these are all subsidiary to the main physiological action which is independent of the character of X Hence, all variations of X are considered equivalent.
  • the compounds of the present invention may be embodied in any of the known pharmaceutical forms for oral, subcutaneous, intramuscular or intravenous administration.
  • the compounds are prepared in solid compositions for oral administration in unit dosage form as tablets, capsules, pills, granules or powders.
  • Solutions, emulsions or suspensions of the compounds of the present invention may be prepared for oral administration. Sterile suspensions or solutions are required for parenteral use and isotonic preparations may also be desirable for injection use.
  • unit dosage form as used in the specification and claims means a physically distinct entity suitable as a unitary dosage for administration, each unit containing a pre-determined quantity of a compound of the present invention.
  • the quantity of the compound contained in the unit dosage form is directly dependant upon the considerations which are well known in the art of compounding a pharmaceutically active material for therapeutic use.
  • the characteristics of the active compound, the particular ice therapeutic elfect to be achieved, the route of administration and the mechanism of the action of the material in the host are important considerations in determining the quantity of the active compound included in the unit dosage form.
  • suitable oral unit dosage forms are capsules, pills, tablets, cachets and powder packets for solid compositions, and teaspoonfuls, dropperf-uls, ampoules and vials for liquid oral dosage forms.
  • the tablets or pills can be laminated or otherwise compounded to provide for time release action of the active compound.
  • the tablet or pill can comprise an inner portion constituting one unit dose and an outer portion constituting another unit dose, the outer portion being in the form of an envelope encompassing the inner portion.
  • the two portions can be separated by an enteric layer which serves to delay the release of the active compound contained in the inner portion by resisting disintegration in the stomach thereby allowing it to pass intact into the intestine where the enteric layer is destroyed releasing the active compound in the inner portion.
  • Such an enteric layer may consist of any number of known substances such as polymeric acids or mixtures thereof, cellulose acetate, cetyl alcohol, shellac and the like.
  • N-benzyl-N,N-dimethyl-N-(2,3-epoxypropyl) -ammonium iodide was mixed with conventional tableting ingredients such as corn starch, lactose, sucrose, stearic acid, sorbitol, talc and functionally similar materials acceptable as pharmaceutical carriers and binders.
  • the solid unit dosage form would contain N-benzylN,N-dimethyl-N-'(2,3-epoxypropyl) -ammonium iodide in an amount of at least 10 mg. and would be administered at a time rate designed to achieve the desired pharmacological result.
  • oral liquid dosage forms examples include aqueous solutions and aqueous or oil suspensions and emulsions wherein the product is dissolved or dispersed in a pharmaceutically acceptable carrier or vehicle.
  • Flavoring agents may be added to increase the palatability of the dosage form.
  • vehicles are cottonseed oil, sesame oil, peanut oil and the like and acceptable dispersing agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, dextran, methyl cellulose and the like.
  • the unit dosage forms containing the compounds of the present invention can include other pharmacologically active compounds such as sedatives, including phenobarbital, barbital and like barbiturates, vitamins, hormones, hypotensive and ataractic agents.
  • the compounds of the present invention may be prepared from the appropriate methylamine by reaction with epichlorohydrin and sodium hydroxide thereby obtaining a tertiary amine reaction product which is then quaternized with an alkylating agent such as a methyl halide to give the desired quaternary ammonium salt.
  • Table I illustrates the therapeutic utility of the compounds of the present invention for the treatment of depression of the central nervous system.
  • N-benzyl-N,N-dimethyl-N (2,3 epoxypropyl) ammonium iodide administered to mice at doses as low as 10 mgm./l g. p. 0. prior to treatment with 5 mgm./kg.
  • reserpine prevented the usual sedative effect of reserpine.
  • mice When mice are pretreated with monoamine oxidase inhibitors before reserpine dosage, the mice exhibit great motor stimulation. Treatment with the compounds of the present invention is advantageous in that they exhibit marked antidepressant activity without the motor stimulation of the usual monoamine oxidase inhibitors.
  • Example 1 The resulting mixture was then poured into 75 ml. of water, the layers were separated, and the aqueous layer was extracted with five -ml. portions of ether. The combined organic layer and ether extracts were then dried over anhydrous sodium sulfate and concentrated under reduced pressure to a pale yellow oil. Distillation of this oil yielded 32.4 g. of colorless N-benzyl-N-(2,3-epoxypropyl)-N-methylamine, B.P. 64/ 0.3 mm.
  • Example 2 N-benzylamine (12.1 g., 0.10 mole) was added to a solution of glycidol (6.36 ml., 0.10 mole) during a period of five minutes. The resulting solution was stored for 24 hours at 25 C. and then concentrated under reduced pressure to a pale yellow oil. This oil was dissolved in 55 ml. of acetone and methyl iodide was added dropwise over a period of five minutes. The reaction mixture was kept at about 25 C. with an ice bath during the addition and stored at 25 C. for 24 hours. The reaction mixture was then poured into 250 ml. of ether and stored for two days at 5 C. The oil was then isolated by decantation and dried under high vacuum, treated with 200 ml.
  • Example 3 Potassium thiocyanate (11.25 g., 0.115 mole) was added to a solution of N-benzyl-N-(2,3-epoxypropyl)-N-methylamine in 30 ml. of methanol and the mixture refluxed for one hour. It was then cooled, poured into 221 ml. of water and this mixture was extracted three times with 100 ml. portions of chloroform. The extracts were combined, dried over sodium sulfate and concentrated to a yellow oil. This oil was then distilled under reduced pressure, the product distilling at 7880 C. at 0.2 mm. of pressure yielding 3.41 g. of N-'nethyl-N-(2,3,-epithiopropyl)benzylamine.
  • Methyl p-toluene sulfonate (7.07 g., 0.038 mole) was added dropwise with stirring to a solution of N-methyl-N- (2,3-epithiopropyl)benzylamine in 25 ml. of freshly distilled acetonitrile. The mixture was allowed to stand at 25 C. for 2 /2 hours. A small amount of ether (2 ml.) was added causing precipitation of a white crystalline solid. The mixture was stored overnight at 4 C. and then the solid was removed by filtration, washed with acetonitrile and dried under reduced pressure. The material was recrystallized from ethanol yielding 8.12 g. of N-benzyl- N,N-dimethyl-N-(2,3-epithiopropyl)ammonium p-toluene sulfonate, M.P. 204-205 C.
  • What I claim is: comprising a pharmaceutical carrier and at least 10 mg. of
  • a pharmaceutical composition comprising a phannaa compound having the formula ceutical carrier and an antidepressant amount of a com- CH3 pound havmg the formula 6 l 6 CH3 X wherein R is a member selected from the group 2,3-epoxypropyl, 2,3-dihydroxypropyl, or 2,3-epithiopropyl, and X 10 is a pharmaceutically acceptable nontoxic anion.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

United States Patent C 3,336,196 ANTIDEPRESSANT COMPOSITIONS Donald Neil McGregor, Syracuse, N.Y., assignor to Bristol-Myers Company, New York, N.Y., a corporation of Delaware No Drawing. Filed July 6, 1964, Ser. No. 380,657 2 Claims. (Cl. 167--65) This invention relates to compositions and a method for treatment and more particularly to quaternary ammonium salts of N,N-dimethylbenzylamines as active ingredients and a method for treatment of psychic depression.
The therapeutic compositions of the present invention comprise a quaternary salt of certain N,N-dimethylbenzylamines as an essential active ingredient in combination with a pharmacologically acceptable anion. The compositions of the present invention possess valuable therapeutic utility as antidepressants and it is the object of the present invention to provide a novel method of counteracting mental depression and apathy without stimulating motor activity.
The therapeutic ingredient is, in the preferred form of the present invention, a quaternary ammonium salt of an N,N-dimethylbenzylamine which can be represented by the following formula:
CHz-N-R wherein R is a member of the group 2,3-epoxypropyl, 2, S-epithiopropyl or 2,3-dihydroxypropyl, and X is a nontoxic anion.
The nontoxic anions which would be pharmaceutically acceptable include the halides (chloride, bromide and' iodide), (lower)alkyl sulfates, the alkyl and aryl sulfonates, phosphate, maleate, fumarate, succinate, tartrate, oxalate and citrate and other ones known to the art. By exchange reactions one of the original variants of X may be replaced with another. The salts obtained through these variations of X may in some cases have special advantages due to solubility, ease of crystallization, lack of objectionable taste, etc. but these are all subsidiary to the main physiological action which is independent of the character of X Hence, all variations of X are considered equivalent.
The compounds of the present invention may be embodied in any of the known pharmaceutical forms for oral, subcutaneous, intramuscular or intravenous administration. Preferably, the compounds are prepared in solid compositions for oral administration in unit dosage form as tablets, capsules, pills, granules or powders. Solutions, emulsions or suspensions of the compounds of the present invention may be prepared for oral administration. Sterile suspensions or solutions are required for parenteral use and isotonic preparations may also be desirable for injection use.
The term unit dosage form as used in the specification and claims means a physically distinct entity suitable as a unitary dosage for administration, each unit containing a pre-determined quantity of a compound of the present invention. The quantity of the compound contained in the unit dosage form is directly dependant upon the considerations which are well known in the art of compounding a pharmaceutically active material for therapeutic use. The characteristics of the active compound, the particular ice therapeutic elfect to be achieved, the route of administration and the mechanism of the action of the material in the host are important considerations in determining the quantity of the active compound included in the unit dosage form. Examples of suitable oral unit dosage forms are capsules, pills, tablets, cachets and powder packets for solid compositions, and teaspoonfuls, dropperf-uls, ampoules and vials for liquid oral dosage forms.
The tablets or pills can be laminated or otherwise compounded to provide for time release action of the active compound. For example, the tablet or pill can comprise an inner portion constituting one unit dose and an outer portion constituting another unit dose, the outer portion being in the form of an envelope encompassing the inner portion. The two portions can be separated by an enteric layer which serves to delay the release of the active compound contained in the inner portion by resisting disintegration in the stomach thereby allowing it to pass intact into the intestine where the enteric layer is destroyed releasing the active compound in the inner portion. Such an enteric layer may consist of any number of known substances such as polymeric acids or mixtures thereof, cellulose acetate, cetyl alcohol, shellac and the like.
In the preferred embodiment of this invention, N-benzyl-N,N-dimethyl-N-(2,3-epoxypropyl) -ammonium iodide was mixed with conventional tableting ingredients such as corn starch, lactose, sucrose, stearic acid, sorbitol, talc and functionally similar materials acceptable as pharmaceutical carriers and binders. The solid unit dosage form would contain N-benzylN,N-dimethyl-N-'(2,3-epoxypropyl) -ammonium iodide in an amount of at least 10 mg. and would be administered at a time rate designed to achieve the desired pharmacological result.
Examples of oral liquid dosage forms include aqueous solutions and aqueous or oil suspensions and emulsions wherein the product is dissolved or dispersed in a pharmaceutically acceptable carrier or vehicle. Flavoring agents may be added to increase the palatability of the dosage form. Examples of vehicles are cottonseed oil, sesame oil, peanut oil and the like and acceptable dispersing agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, dextran, methyl cellulose and the like.
i The unit dosage forms containing the compounds of the present invention can include other pharmacologically active compounds such as sedatives, including phenobarbital, barbital and like barbiturates, vitamins, hormones, hypotensive and ataractic agents. The compounds of the present invention may be prepared from the appropriate methylamine by reaction with epichlorohydrin and sodium hydroxide thereby obtaining a tertiary amine reaction product which is then quaternized with an alkylating agent such as a methyl halide to give the desired quaternary ammonium salt. The following equations illustrate the procedure for preparation of N-benzyl-N-(2,3-epoxypropyl)-N-methylamine using benzaldehyde, methylamine and epichlorohydrin as reagents for illustrative purposes and the subsequent quaternization of that compound with methyl iodide to obtain N benzyl N,N dimethyl-N-(2,3-epoxypropyl)-ammonium iodide.
CHO Ha CHzNHCHz CHQNHI =om-N-on, NaOH 1 CHa N-CHz- C H C HI Table I illustrates the therapeutic utility of the compounds of the present invention for the treatment of depression of the central nervous system. For example, N-benzyl-N,N-dimethyl-N (2,3 epoxypropyl) ammonium iodide administered to mice at doses as low as 10 mgm./l g. p. 0. prior to treatment with 5 mgm./kg. reserpine prevented the usual sedative effect of reserpine. An oral dosage of 1682 mgm./kg. proved lethal to fifty percent of the mice. When mice are pretreated with monoamine oxidase inhibitors before reserpine dosage, the mice exhibit great motor stimulation. Treatment with the compounds of the present invention is advantageous in that they exhibit marked antidepressant activity without the motor stimulation of the usual monoamine oxidase inhibitors.
CH CHPNQR Ha I TABLE I Dose Lethal to 50%, mgmJkg.
Minimum Efiective Dose, mgm./kg. p.o.
The following examples are given to illustrate the scope of this invention without limiting it thereto.
Example 1 The resulting mixture was then poured into 75 ml. of water, the layers were separated, and the aqueous layer was extracted with five -ml. portions of ether. The combined organic layer and ether extracts were then dried over anhydrous sodium sulfate and concentrated under reduced pressure to a pale yellow oil. Distillation of this oil yielded 32.4 g. of colorless N-benzyl-N-(2,3-epoxypropyl)-N-methylamine, B.P. 64/ 0.3 mm.
Analysis.Calculated for C H NO: C, 74.53; H, 8.53; N, 7.90. Found: C, 74.55; H, 8.52; N, 7.88.
To a stirred, cooled (ice bath) solution of N-benzyl- N-(2,3-epoxypropyl)-N-methylamine (9.0 g., 0.051 mole) in 75 ml. of acetonitrile was added dropwise methyl iodide (9.5 g., 0.15 mole) during 20 minutes. After the addition was complete, the ice bath was removed and the mixture was stored at room temperature overnight. The reaction mixture was then diluted with 200 ml. of ether and, after seeding and cooling, the crystalline precipitate was removed by filtration. Reprecipitation from acetonitrile with ether yielded 14.9 g. of N-benzyl-N, N-dimethyl-N-(2,3-epoxypropyl)-ammonium iodide in the form of colorless crystals, M.P. 9799 C.
Analysis.Calculated for C H INO: C, 45.2; H, 5.69; N, 4.39. Found: C, 45.20; H, 5.65; N, 4.29.
Example 2 N-benzylamine (12.1 g., 0.10 mole) was added to a solution of glycidol (6.36 ml., 0.10 mole) during a period of five minutes. The resulting solution was stored for 24 hours at 25 C. and then concentrated under reduced pressure to a pale yellow oil. This oil was dissolved in 55 ml. of acetone and methyl iodide was added dropwise over a period of five minutes. The reaction mixture was kept at about 25 C. with an ice bath during the addition and stored at 25 C. for 24 hours. The reaction mixture was then poured into 250 ml. of ether and stored for two days at 5 C. The oil was then isolated by decantation and dried under high vacuum, treated with 200 ml. of warm acetone and stirred at 5 C. overnight. Crystalline product was removed by filtration, treated with boiling acetone and the solid removed by filtration and washed with acetone and dried yielding 13.0 g. of N benzyl-N-(2,3-dihydroxypr0pyl)-N,N-dimethylammonium iodide, M.P. 124-125 C.
Analysis.Calculated for C H NO I: C, 42.8; H, 5.98; N, 4.16. Found: C, 42.80; H, 5.92; N, 4.22.
Example 3 Potassium thiocyanate (11.25 g., 0.115 mole) was added to a solution of N-benzyl-N-(2,3-epoxypropyl)-N-methylamine in 30 ml. of methanol and the mixture refluxed for one hour. It was then cooled, poured into 221 ml. of water and this mixture was extracted three times with 100 ml. portions of chloroform. The extracts were combined, dried over sodium sulfate and concentrated to a yellow oil. This oil was then distilled under reduced pressure, the product distilling at 7880 C. at 0.2 mm. of pressure yielding 3.41 g. of N-'nethyl-N-(2,3,-epithiopropyl)benzylamine.
Methyl p-toluene sulfonate (7.07 g., 0.038 mole) was added dropwise with stirring to a solution of N-methyl-N- (2,3-epithiopropyl)benzylamine in 25 ml. of freshly distilled acetonitrile. The mixture was allowed to stand at 25 C. for 2 /2 hours. A small amount of ether (2 ml.) was added causing precipitation of a white crystalline solid. The mixture was stored overnight at 4 C. and then the solid was removed by filtration, washed with acetonitrile and dried under reduced pressure. The material was recrystallized from ethanol yielding 8.12 g. of N-benzyl- N,N-dimethyl-N-(2,3-epithiopropyl)ammonium p-toluene sulfonate, M.P. 204-205 C.
Analysis.Calculated for C H NO S C, 60.12; H, 6.64; N, 3.69. Found: C, 59.95; H, 6.53; N, 3.96.
What I claim is: comprising a pharmaceutical carrier and at least 10 mg. of
1. A pharmaceutical composition comprising a phannaa compound having the formula ceutical carrier and an antidepressant amount of a com- CH3 pound havmg the formula 6 l 6 CH3 X wherein R is a member selected from the group 2,3-epoxypropyl, 2,3-dihydroxypropyl, or 2,3-epithiopropyl, and X 10 is a pharmaceutically acceptable nontoxic anion.
References Cited UNITED STATES PATENTS wherein R is a member selected from the group 2,3-epoxy- 15 33287575 11/1966 McGregor 167 65 propyl, 2,3-dihydroxypropyl, or 2,3-epithiopr0pyl, and X is a pharmaceutically acceptable nontoxic anion. ALBERT Pnmwy Exammer' 2. A pharmaceutical composition in unit dosage form S. I. FRIEDMAN, Assistant Examiner.

Claims (1)

1. A PHARMACEUTICAL COMPOSITION COMPRISING A PHARMACEUTICAL CARRIER AND AN ANTIDEPRESSANT AMOUNT OF A COMPOUND HAVING THE FORMULA
US380657A 1964-07-06 1964-07-06 Antidepressant compositions Expired - Lifetime US3336196A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US380657A US3336196A (en) 1964-07-06 1964-07-06 Antidepressant compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US380657A US3336196A (en) 1964-07-06 1964-07-06 Antidepressant compositions

Publications (1)

Publication Number Publication Date
US3336196A true US3336196A (en) 1967-08-15

Family

ID=23502006

Family Applications (1)

Application Number Title Priority Date Filing Date
US380657A Expired - Lifetime US3336196A (en) 1964-07-06 1964-07-06 Antidepressant compositions

Country Status (1)

Country Link
US (1) US3336196A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3475458A (en) * 1967-08-11 1969-10-28 Shell Oil Co Production of epoxy ammonium salts
US3520970A (en) * 1966-08-12 1970-07-21 Roehm & Haas Gmbh Solid oral drug medicament coated for rapid or gradual release with copolymers of polymerizable quaternary ammonium monomers and water-insoluble homopolymer-forming monomers
US3965178A (en) * 1973-08-19 1976-06-22 Continental Oil Company Method for preparing tetrabutylammonium bromide
US4737309A (en) * 1985-03-13 1988-04-12 Regents Of The University Of Minnesota Liquid membrane system for the removal of nitrate from water

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3287375A (en) * 1964-07-06 1966-11-22 Bristol Myers Co Nu, nu-dimethyl-nu-(2, 3-epoxypropyl)-omicron-substituted benzylammonium salts

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3287375A (en) * 1964-07-06 1966-11-22 Bristol Myers Co Nu, nu-dimethyl-nu-(2, 3-epoxypropyl)-omicron-substituted benzylammonium salts

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3520970A (en) * 1966-08-12 1970-07-21 Roehm & Haas Gmbh Solid oral drug medicament coated for rapid or gradual release with copolymers of polymerizable quaternary ammonium monomers and water-insoluble homopolymer-forming monomers
US3475458A (en) * 1967-08-11 1969-10-28 Shell Oil Co Production of epoxy ammonium salts
US3965178A (en) * 1973-08-19 1976-06-22 Continental Oil Company Method for preparing tetrabutylammonium bromide
US4737309A (en) * 1985-03-13 1988-04-12 Regents Of The University Of Minnesota Liquid membrane system for the removal of nitrate from water

Similar Documents

Publication Publication Date Title
US3174901A (en) Process for the oral treatment of diabetes
US3542872A (en) 1-amino substituted phenoxy-2-hydroxy-3-isopropylamino-propanes
US3663696A (en) Treatment of depression with 2-chloro-11 - (piperazinyl)dibenz - (b,f)(1,4)oxazepines and acid addition salts thereof
DE1770153C3 (en) Heterocyclic aminoketones, their pharmacologically acceptable acid addition salts and process for their preparation
JPS5877868A (en) Pyridazine derivative, manufacture and central nervous system activator
JPH0150700B2 (en)
US3336196A (en) Antidepressant compositions
DE2115926B2 (en) 1- (4-HYDROXY-3-DIMETHYLAMINOSULFAMIDOPHENYL) -2-AMINOETHANE DERIVATIVES, THE PROCESS FOR THEIR PREPARATION AND AGENTS CONTAINING THESE
US3959470A (en) Psychotropic medicinal preparation
US3336195A (en) Composition for use in the treatment of psychic depression
US2918407A (en) Anti-spasmodics specific for upper gastrointestinal pain and spasm
US3733410A (en) Elixirs with acid addition salts of therapeutically active organic bases as active substances
US3313686A (en) Palatable antitussive agent-resin complex
US3274054A (en) Antiviral compositions and method of administration
US3274055A (en) Acid addition salts of morpholine ethanol
US3266988A (en) Method of producing anti-adrenal activity
US3311539A (en) Method of treating traumatized nerves
US3553331A (en) Pharmaceutical compositions and methods utilizing 4-alkyl-1,4-dimethycyclo-hexylamines and 4-alkyl-1,4-dimethylcyclohexanemethylamines
US3422191A (en) Compositions and methods for tranquilization employing salts of n-morpholine ethanol
US3261750A (en) Method of curbing appetite
US3083139A (en) Therapeutic 1-(1, 2-diphenylethyl) pyrrolidine for the management of depression
US3681498A (en) Isothiazolyl pyridinium salts as hypoglycemic agents
US2820739A (en) Antitussive compositions
US3629418A (en) Process for producing an anti-depressant effect with piperazine quinolines
US3138529A (en) Tetracycline antibiotic compositions for oral use